Research News
View articles by month and year
11–20 of 32 articles
-
Nexavar May Help Treat Some Metastatic Breast Cancers
Research suggests that some women diagnosed with advanced-stage breast cancer benefit more from chemotherapy and Nexavar compared to chemotherapy and placebo (a sugar pill).
-
New Medicines That Slow Cancer’s Growth Don’t Seem to Improve Survival
Research shows no link between progression-free survival and overall survival in experimental breast cancer treatment trials.
-
Avastin Slows Growth of Metastatic Breast Cancer
Women diagnosed with metastatic breast cancer who got Avastin in combination with chemotherapy lived 1 to 3 months longer without the cancer growing compared to women who only got chemotherapy, but overall survival was the same for both groups.
-
Avastin Not Recommended to Treat Breast Cancer by British Agency
Echoing the FDA decision, the British National Institute for Health and Clinical Excellence hasn't approved using Avastin to treat metastatic breast cancer.
-
Genentech Asks FDA for Full Hearing on Avastin
Genentech, the company that makes Avastin, has asked for a full FDA hearing to again present currently available research on Avastin and to review plans for future research.
-
Women Treated with Avastin Have Higher Risk of Congestive Heart Failure
Women treated with Avastin for advanced-stage breast cancer were four to five times more likely to develop congestive heart failure compared to women who didn't get Avastin. Still, the overall risk of heart failure was low.
-
Researchers Recommend Having Port in Place for Week Before Starting Avastin
Research shows that doctors should wait at least 1 week after a venous access line is put in before giving Avastin.
-
Real World Survival Stats for Avastin Mirror Clinical Results
Analysis shows that the real world survival statistics of women diagnosed with metastatic breast cancer and treated with chemotherapy and Avastin were similar to survival statistics of women in clinical trials looking at the same combination.
-
Avastin Added to Chemo Before Surgery Offers No Benefit
Research shows that adding Avastin to neoadjuvant chemotherapy doesn't seem to benefit women diagnosed with early-stage or locally-advanced breast cancer.
-
Herceptin-Avastin-Taxotere Combo Can Help Treat Metastatic HER2-Positive Breast Cancer
A small, very early study found that about 78% of women diagnosed with metastatic, HER2-positive breast cancer got some benefit from a combination of Herceptin, Avastin, and Taxotere as a first treatment.
11–20 of 32 articles
